A 27 – New York
Introduced: 2018 Status: Inactive / Dead
A health maintenance organization or insurer shall not by contract or in any other manner refuse to accept premium or any required cost sharing payments from third parties if made by (a) an Indian tribe, …
A 2713 – New Jersey
Introduced: 2018 Status: Inactive / Dead
EXPANDS SCOPE OF CLAIMS SUBJECT TO “HEALTH CLAIMS AUTHORIZATION, PROCESSING AND PAYMENT ACT,” AND MODIFIES CERTAIN CLAIMS PROCEDURES. This bill expands the scope of claims subject to sections 3 through 7 of the “Health Claims Authorization, …
A 2718 – New York
Introduced: 2017 Status: Inactive / Dead
Relates to the authority of nurse practitioners and physician assistants to prescribe certain services.
A 2733 (see companion bill S 5588) – New York
Introduced: 2017 Status: Inactive / Dead
COLLABORATIVE PROGRAMS FOR COMMUNITY PARAMEDICINE SERVICES AS PART OF THE HOSPITAL-HOME CARE-PHYSICIAN COLLABORATION PROGRAM: The Hospital-home care-physician collaboration program shall provide a framework to support voluntary initiatives in collaboration to improve patient care access and …
A 274 – New York
Introduced: 2017 Status: Inactive / Dead
Establishes the Medicaid identification and anti-fraud biometric technology pilot program; appropriates money therefor
A 2765 (see companion bill S 4502) – New York
Introduced: 2019 Status: Inactive / Dead
Requires notification to insureds that an out-of-network physician may be used in their procedure, test or surgery and such physician’s services shall not be covered by their insurance policy; such services must be covered if …
A 277 – New Jersey
Introduced: 2020 Status: Enacted
Requires public members of Drug Utilization Review Board to disclose financial interests and benefits received from and investment interests held in pharmaceutical distributors, pharmaceutical manufacturers, or pharmacy benefits managers.*
A 2789 (see companion bill S 1065) – New Jersey
Introduced: 2022 Status: In Process
In the event that a laboratory that performs an HIV screening test under the bill is out-of-network with respect to a covered person’s health benefits plan, the carrier is to reimburse the laboratory for the …
A 2789 (see companion bill S 1119) – New Jersey
Introduced: 2020 Status: Inactive / Dead
Establishes limitations on and conditions associated with prescribers’ acceptance of compensation from pharmaceutical manufacturers.
A 2791 – New Jersey
Introduced: 2020 Status: Inactive / Dead
Requires pharmaceutical manufacturers and wholesale distributors accept and provide a rebate for certain returned drugs.
A 2809 – New Jersey
Introduced: 2022 Status: In Process
Permits import of Canadian prescription drugs.
A 2821 (see companion bill S 1109) – New Jersey
Introduced: 2020 Status: Inactive / Dead
Establishes New Jersey Commission on Health Insurance Network Adequacy. This bill establishes the New Jersey Commission on Health Insurance Network Adequacy. The purpose of this commission is to review the network adequacy regulations adopted by …
A 2827 – New Jersey
Introduced: 2020 Status: Inactive / Dead
THE “HEALTH CARE PROVIDER NETWORK TRANSPARENCY ACT”; ESTABLISHES REQUIREMENTS FOR GRANTING ACCESS TO CERTAIN HEALTH CARE PROVIDER DISCOUNTS. This bill establishes requirements for granting access to provider discounts under a provider network contract, in order …
A 2839 – New York
Introduced: 2019 Status: Inactive / Dead
Requires insurance companies to issue joint checks for payment to an insured and a health care provider in certain circumstances. An insurance company subject to article thirty-two of this chapter, shall issue and provide an …
A 2839 (see companion bill S 1614) – New Jersey
Introduced: 2022 Status: In Process
This bill places a flat cap on the out-of-pocket contribution for any covered person prescribed insulin, an epinephrine auto-injector device, or a prescription asthma inhaler across insurance providers. Coverage for these items may not be …
A 2840 (see companion bill S 1615) – New Jersey
Introduced: 2022 Status: In Process
Establishes certain data reporting requirements for prescription drug supply chain; requires Division of Consumer Affairs to issue annual report on emerging trends in prescription drug pricing